Drugs / Magnesium glycinate
Magnesium glycinate
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07655817 | Jul → Dec 2026 expected | delirium, magnesium deficiency | Tanta University | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06996171 | May → Aug 2025 overdue | insomnia | CMH Kharian Medical College | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Magnesium glycinate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06996171 ↗ |
| Known as | Bis(glycinato-n,o)magnesium | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108424 ↗ |
| Known as | Magnesium bisglycinate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108424 ↗ |
| Route | Oral | “Oral, Tablet, Dose 500mg/day at night” NCT06996171 ↗ |